What if market access risk could be identified, quantified and addressed before it impacts product uptake?
In a newly published article for Pharmaceutical Market Europe (PME), Dr David Cunningham, Senior Consultant here at Visions4Health, explores the thinking behind DCODE® (Disease Cost Outcomes Data Environment) – our proprietary market access risk assessment tool designed to help life sciences companies navigate an increasingly complex UK healthcare landscape.
As NHS financial pressures intensify and market access pathways become more challenging to predict, pharmaceutical companies face growing uncertainty around product launch, adoption and long-term uptake. DCODE® was developed to address this challenge, providing a structured, evidence-based approach to identifying risks and opportunities across the product lifecycle.
Drawing on more than 20,000 data points and a framework covering 54 UK market access scenarios, DCODE® delivers an independent assessment of market access readiness, helping organisations make more informed strategic decisions and focus resources where they can have the greatest impact.
In the article, David discusses:
- Why UK market access has become increasingly difficult to predict
- The challenges facing life sciences companies in today’s NHS environment
- How DCODE® helps identify and benchmark access risks
- The importance of local NHS insight in driving product adoption
- How organisations can use data-driven assessments to optimise launch and market access strategies
The article provides an inside look at the methodology behind DCODE® and demonstrates how a structured, reproducible approach can help reduce uncertainty and support better commercial and access outcomes.
Read the full article in Pharmaceutical Market Europe.
If you are looking to cut through uncertainty and build a market access strategy that works in today’s NHS, or you want to learn more about DCODE® and how it can help you, we’d love to talk
